Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR<sup>®</sup>) for the management of acromegaly - Concepedia

Concepedia

Publication | Closed Access

Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR<sup>®</sup>) for the management of acromegaly

139

Citations

29

References

1998

Year

P.H. O'Connor Davies, Susan E. Stewart, Ioana Lancranjan, Michael C. Sheppard, Paul M. Stewart

Clinical Endocrinology

Abstract

We conclude that SMS-LAR is a safe, effective and well tolerated treatment, making it an important therapeutic option in the management of acromegaly.

References

	Year	Citations

Page 1